We have demonstrated that, in Escherichia coli, quinolone antimicrobial agents target topoisomerase IV (topo IV). The inhibition of topo IV becomes apparent only when gyrase is mutated to quinolone resistance. In such mutants, these antibiotics caused accumulation of replication catenanes, which is diagnostic of a loss of topo IV activity. Mutant forms of topo IV provided an additional 10-fold resistance to quinolones and prevented drug-induced catenane accumulation. Drug inhibition of topo IV differs from that of gyrase. (i) Wild-type topo IV is not dominant over the resistant allele. (ii) Inhibition of topo IV leads to only a slow stop in replication. (iii) Inhibition of topo IV is primarily bacteriostatic. These differences may result from topo IV acting behind the replication fork, allowing for repair of drug-induced lesions. We suggest that this and a slightly higher intrinsic resistance of topo IV make it secondary to gyrase as a quinolone target. Our results imply that the quinolone binding pockets of gyrase and topo IV are similar and that substantial levels of drug resistance require mutations in both enzymes.
tions in both enzymes.
The quinolone antibacterial agents have had a long and important history in the clinic and in basic research. The biological activity of the founding member of the group, nalidixic acid, was discovered in 1965 (1) . Successive generations of drugs have brought orders of magnitude increases in efficacy and they are now one of the most widely used classes of antibacterial agents. The primary target of these drugs in Escherichia coli was established in 1977 as DNA gyrase, a type-2 topoisomerase (2, 3) . The critical role of gyrase is to unlink chromosomal DNA during its replication by the introduction of negative supercoils (4, 5) . The quinolones inhibit gyrase activity in vitro and a single amino acid change can cause a 10-to 100-fold decrease in drug sensitivity (6) .
The potency of the quinolones is caused by their striking mode of action. It was shown in 1979 that they block DNA synthesis not by depriving the cell of gyrase but by converting gyrase to a poison of replication (7) . Anticancer drugs that inhibit human type-2 topoisomerases also convert their targets into poisons (8) . The poisoning is mediated by trapping of an intermediate in topoisomerizatiorn, which ultimately leads to a double-strand break of DNA (9) .
A number of results have implicated secondary targets for quinolones. Chief among these is the multistep resistance to quinolones that occurs clinically, in which mutations in gyrase are only an initial step (10) . A second bacterial type-2 topoisomerase was discovered with a sequence similar to that of gyrase, particularly in the region responsible for drug sensitivity (11) . This essential enzyme, topoisomerase IV (topo IV), is required for the terminal stages of unlinking of DNA during replication (11, 12) . The first evidence that topo IV might be a quinolone target was the demonstration that it is inhibited by quinolones in vitro almost as well as gyrase (13) . Recently,
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comparative analyses of DNA sequences have been adduced to imply that topo IV is the primary target of quinolones in Staphylococcus aureus and the secondary one in Neisseria gonorrhea (14, 15) . What has been lacking is a direct demonstration that topo IV is a quinolone target in any organism by showing that drug-resistant mutants encode a resistant topo IV and that a signature activity of topo IV is inhibited in vivo by quinolones.
The observation that mutations in topo IV cause accumulation of catenated intermediates in DNA replication provides just such an assay (12) . We find that quinolones induce catenane accumulation in E. coli if gyrase is first protected from inhibition by mutation. We constructed, and found in a clinically resistant strain, mutations in topo IV that result in resistance to quinolones in vivo and with purified enzymes in vitro. We also show that the mode of topo IV inhibition is different from that of gyrase, and this difference is a major reason why topo IV is a secondary target for these drugs in E. coli.
MATERIALS AND METHODS
Strains, Plasmids, Enzymes, and Assays. Bacterial strains and plasmids are shown in Table 1 . The GyrA and GyrB subunits of DNA gyrase were purified to homogeneity as described (18) . ParC, ParC"-0, ParCK84, and ParE were purified to .95% homogeneity (19) . Norfloxacin, ciprofloxacin, nalidixic acid, and oxolinic acid were obtained from Sigma; fleroxacin and 2-pyridones were from Abbott. DNA supercoiling by DNA gyrase was assayed as described (20 
RESULTS
Inhibition of Purified Topo IV and DNA Gyrase by Quinolones. We assayed eight different quinolones to determine whether any were more effective on purified topo IV than on gyrase. Our hope was that with such a drug we could determine whether topo IV was a target in vivo by assaying for accumulated catenated intermediates (12, 28) . The drugs included the archetype of the quinolone family, nalidixic acid; the clinically important ciprofloxacin, norfloxacin, and fleroxacin; and representatives of a new generation of drugs, the 2-pyridones (22) . Our assays were cleavage of duplex DNA, relaxation and decatenation for topo IV, and supercoiling for gyrase. All of the drugs were -2-fold less effective on topo IV than on gyrase, even though the Ki values for the drugs varied by 2 orders of magnitude (Table 2) .
Therefore, all the drugs tested were inhibitors of topo IV in vitro, but none inhibited it preferentially.
Norfloxacin Causes Catenane Accumulation in DrugResistant Gyrase Mutants. Given the lack of preferential inhibition of topo IV in vitro, we used a genetic means to attenuate quinolone inhibition of gyrase in vivo. We used a gyrase mutant (gyrAr; S83L) that is 10-to 100-fold more resistant than the wild-type (wt) strain to a range of quinolones (6) . We assayed for inhibition of topo IV in the gyrAr mutant by accumulation of catenated pBR322 or pCM600. We used three control assays for DNA gyrase function in vivo. The first was DNA synthesis. The conversion of gyrase to a replication poison by drugs immediately stops DNA synthesis (1), whereas topo IV is not required for synthesis (12) . The second was DNA supercoiling. Gyrase is uniquely required for the introduction of negative supercoils, whereas topo IV has no appreciable role in the maintenance of supercoiling (12) . The third is DNA knotting, which increases upon inhibition of gyrase (23) but not of topo IV (12) . Fig. 1A shows that DNA synthesis was reduced by two-thirds at 0.4 and 50 ,M norfloxacin for gyrA+ and gyrAr strains, respectively. This sets the range over which we could assay for inhibition of topo IV in the gyrAr mutant. Higher concentrations would block DNA gave the ladder and amounts of catenated replication intermediates characteristic for topo IV inhibition (Fig. 1B) . Similar results were obtained with plasmid pCM600 (data not shown). The optimal concentrations of norfloxacin for catenane accumulation were 15-30 ,M. These catenanes must derive from replication because they have the characteristic electrophoretic pattern and are absent at drug doses that block DNA synthesis (lanes 5 and 6).
Norfloxacin did not cause catenane accumulation in gyrA+ strains, where it instead blocked DNA replication (Fig. 1B) . We confirmed by two additional assays that gyrase was not inhibited by norfloxacin, at the levels used, in the gyrAr strain. First, knotting was seen at drug concentrations 10-fold higher than catenanes were (Fig. 1B) . Second, the supercoiling of plasmid pBR322 was unchanged in the gyrAr strains at norfloxacin concentrations that induced catenation of the same plasmid (data not shown). An effect on supercoiling was not seen until drug levels exceeded 60 ,uM in the gyrAr strain.
Quinolones Cause High Levels of Catenane Accumulation of Newly Synthesized DNA. The relatively low levels of catenanes seen in Fig. 1B and in topo IV mutants at the nonpermissive temperature represent the steady-state amount (12) . Pulse labeling with [3H]thymidine showed that nearly all of the newly replicated plasmids in topo IV mutants proceeded through catenated intermediates (28) . Therefore, we analyzed the effect of quinolones on newly replicated plasmid DNA in gyrAr cells. Cells were labeled for 1 min with [3H]thymidine after a 15-min preincubation with 15 ,uM norfloxacin. The plasmid DNA was isolated, nicked, and resolved by agarose gel electrophoresis. Half of the labeled plasmid DNAwas catenated, ranging in complexity from 2 to 68 nodes ( Fig. 2A) , the same profile as found in topo IV mutafits after a 1-min pulse (28) . Plasmid supercoiling, and thus gyrase activity, was not affected by the drug (Fig. 2B) . Although we used norfloxacin in most of our experiments, other quinolones also inhibited topo IV in the gyrAr strain. For a 1-min pulse, 40 ,uM ciprofloxacin or 27 ,uM fleroxacin led to incorporation of one-half of the label into catenanes.
A Mutation in parC Confers Quinolone Resistance in Vitro. The single amino acid change in gyrase that causes the greatest resistance to quinolones is S83L in GyrA (24), the mutation was overexpressed and purified to homogeneity. Enzymatic activity was reconstituted by adding purified ParE to either ParCL80 or ParC+. The enzymes had similar specific activities-2 x 106 relaxation units per mg of protein. Relaxation was 50% inhibited at 7 ,uM with wt topo IV but required 75 ,uM norfloxacin with the mutant enzyme (Fig. 3A) . Similar results were obtained for norfloxacin-induced cleavage (Fig. 3B) . The CC5o for topo IV'80 was 62 ,uM compared to 6 ,uM for topo IV+ (Fig. 3B) . Inhibition of decatenation gave the same relative difference between the ParCL80-and ParC+-containing enzymes. Thus, the S80L mutation causes a 10-fold increase in resistance to norfloxacin for topo IV, roughly the same increase in resistance as Ser-83 to Leu causes in gyrase.
ParCL80 Confers Quinolone Resistance to a GyrAr Strain. To determine whether ParCL80 confers resistance to norfloxacin in vivo, we constructed four isogenic strains that carry the gyrA + or gyrAr allele and the parC+ or parCL80 gene in all pairwise combinations. The single colony survival results are shown in Fig. 4 . The concentration of norfloxacin that inhibited growth by one-half for the parCL80 gyrAr strain was -6 times higher than that for theparC+ gyrAr mutant. TheparCL80 mutation did not confer any drug resistance to the gyrA'-containing strains. Similar results were obtained with ciprofloxacin and fleroxacin. These results establish that topo IV is a target of quinolones in vivo.
We used the single (gyrAr) and double (parCL80 gyrAr) drug-resistant mutants to test whether inhibition of topo IV was solely responsible for accumulation of replication catenanes. If topo IV were indeed the drug target in the gyrAr strain, then catenanes should no longer accumulate when topo IV is made drug resistant. This is the result we obtained (Fig.  2C) . Thus, the change of Ser-80 to Leu renders topo IV drug resistant in vivo and in vitro. A Quinolone-Resistant Clinical Isolate Has a Mutant Topo IV. Does a drug-resistant mutation inparC also occur in nature? A clinical strain, 205096, has been isolated that contains several mutations that collectively confer 1000-fold resistance to quinolones (16) . This strain has mutations in Ser-83 and Asp-87 of GyrA, and we predicted that topo IV was also mutated. To test this, we sequenced 351 nucleotides ofparC in strain 205096. We found only 1 nucleotide change leading to an E84K mutation. Mutations in the homologous residue in DNA gyrase confer drug resistance, although not as well as the S83L mutation (24) . The purified mutant ParCK84 plus ParE was 25-fold more resistant to norfloxacin than the reconstituted enzyme containing ParC+. We constructed the test strains identical to those used above and found in vivo that the naturally occurring mutation inparC caused 10-fold more resistance than gyrAr alone (Fig. 4)- (Fig. 5A ). This contrasts with the rapid inhibition of DNA replication in gyrA + strains (Fig. SA) . This characteristic rapid block in replication results because the drug converts gyrase into a potent poison of DNA replication (7). Removal of gyrase activity by mutation causes a much slower diminution of DNA synthesis (7) .
Another manifestation of the poison effect is the dominance of gyrAI over gyrAr (25) . Eukaryotic type-2 topoisomerases are also made into poisons by anticancer agents and the wt allele is also dominant over the resistant allele (26) . For catalytic inhibitors, which act by depriving the cell of their targets, the resistant allele should be dominant. To test dominance for topo IV, we constructed all combinations with parC+ orparCr alleles expressed from the chromosome and from plasmids, either single copy or multicopy. We measured the effect of norfloxacin on colony formation (Fig. SB) . With parC on a single copy plasmid and the chromosome, the heterozygote is midway in sensitivity between the homozygous wt and resistant strains-i.e., codominance. Multicopy plasmids do not alter the phenotype of homozygous strains. However, the multicopy allele (whether parC+ or parCr) dominates for the heterozygotes. Therefore, the dominance tests give results different from that obtained with either classical topoisomerase poisons or catalytic inhibitors. DISCUSSION Topo IV Is a Quinolone Target in Vivo. We have established that topo IV is a target for quinolones in E. coli. This was not apparent in earlier studies of wt strains because bactericidal antigyrase concentrations of drug were lower than that needed to target topo IV. Even at drug concentrations that inhibited both topoisomerases, the gyrase effect was epistatic because of an immediate poisoning of DNA replication. Two results establish that topo IV is a quinolone target. First, in agyrAr strain, these drugs caused accumulation of replication catenanes and cell death without a significant effect on DNA replication (Figs. 1 and  4) . The fraction of DNA that is catenated and the catenane node distribution ( Fig. 2A) were identical to those seen in topo IV mutants (12, 28) . Second, we constructed two mutant forms of ParC that conferred 5-or 10-fold additional quinolone resistance to a gyrAr strain (Fig. 4) . Topo IV reconstituted from the purified mutant forms of ParC was 10-and 25-fold more drug resistant than wt enzyme (Fig. 3) . Moreover, quinolones did not cause catenane accumulation in the gyrase and topo IV drug-resistant double mutant strain (Fig. 2C) .
Additional evidence indicates that topo IV is a quinolone target in vivo. First, a single mutation in gyrA of E. coli leads to a 100-fold resistance to quinolones as measured by the arrest of DNA synthesis (Fig. 1A) . At the same time, resistance measured by colony-forming ability goes up only 10-fold (Fig.  4) . The discrepancy is due to topo IV, because gyrAr mutants that are also parCr are an additional 10-fold more resistant (Fig. 4) . Second, sequence analysis of genes that are homologous to E. coli parC led to the conclusion that mutations in parC can confer quinolone resistance to S. aureus (14) and N. gonorrhea (15) . S. aureus has, presumably, a naturally drugresistant gyrase (27) , and S80F or S80Y mutations in the ParC homolog gave 10-to 15-fold resistance. In this organism, therefore, topo IV seems to be the primary target for quinolones. In the N. gonorrhea study, topo IV was concluded to be a secondary target. The change S88F in the parC homolog caused 8-fold resistance to quinolones but only if the strain already had a gyrase-resistance mutation. Mutation E91K provided an additional 4-fold resistance. Thus, in both species, quinolone-resistant mutations in parC occurred in positions homologous to ones that we demonstrated confer drug resistance to E. coli.
Why Topo IV Is Secondary to Gyrase as a Quinolone Target. Why is DNA gyrase, and not topo IV, the primary quinolone target in E. coli? The possible explanations include (i) the intrinsic sensitivity of topo IV to quinolones is less than that of gyrase; (ii) the in vivo conditions selectively diminish the inhibition of topo IV; and (iii) the modes of action of the enzymes translate into less efficient drug inhibition of topo IV. We believe that possibility iii is the major reason why topo IV is secondary to gyrase as a quinolone target, but that i makes a contribution as well.
We tested the first possibility by studying the relative sensitivities of purified DNA gyrase and topo IV to a variety of quinolone drugs in vitro (Table 2) . For all the drugs, gyrase was only 2-fold more sensitive than topo IV. This difference cannot explain the 10-fold increase in minimal inhibitory concentration resulting from a drug-resistant mutation in gyrase. We conclude that although topo IV is intrinsically slightly less sensitive to quinolones than gyrase, this is not the major reason why it is a secondary target. In considering the second possibility, we note that supercoiling (gyrase) and decatenation (topo IV) were inhibited by 50%, respectively, at 6 and 15 ,uM norfloxacin in vivo ( Fig. 1; data not shown) . We conclude that topo IV is only 2-3 times less sensitive to quinolones than DNA gyrase in vivo.
We now turn to possibility iii. The primary effect of quinolones on bacteria is instant arrest of DNA replication at drug concentrations that kill the cell (1). A single mutation in gyrase rescues DNA replication and viability (6, 25) . Bactericidal drug concentrations are 100 times lower than concentrations that inhibit gyrase supercoiling activity in vivo because quinolones convert gyrase to a poison (7) . Because the gyrAr strain we used is 10 times more resistant to quinolones than wt cells, andparCr introduces another 10-fold resistance, the targeting of topo IV seems to occur at 10 times higher drug concentrations than the targeting of gyrase. This contrasts with in vitro and in vivo results that topo IV is only 2-3 times less sensitive to norfloxacin than DNA gyrase.
If a target topoisomerase acts ahead of and close to the replication fork, then cleaved adducts will rapidly block replication. If a topoisomerase acts behind the fork, we expect replication to die out slowly. The rapid replication arrest at drug concentrations that affect only gyrase suggests that gyrase acts in front of the fork. Topo IV inhibition by drug (in a gyrAr strain) results in a gradual decrease in replication that coincides with cell death (Fig. SA) . We suggest that this results from topo IV acting behind the fork and that the presence of an intact sister chromosome allows repair of the double-strand break. Thus, the conversion of the topo IV adduct to a lethal lesion is less likely. We speculate that this explains the slower rate and higher dose for topo IV-mediated killing. This model can also explain the dominance results. When ParCr and ParC+ were roughly equal, an intermediate level of resistance resulted (Fig.  SB) . With multicopy plasmids, the allele on the plasmid dominated. We suggest that the resistant and wt ParC compete for DNA and the probability of death is proportional to the number of lesions. Thus, these drugs may convert topo IV to a poison just as readily as they do gyrase, but killing is limited because the poison is slower acting and lesion repair provides an antidote.
Quinolone inhibition of topo IV is primarily bacteriostatic, as shown by the dramatic drop in colony-forming ability at drug concentrations that had a modest effect on viability (Figs. 4  and 5A ). After addition of drug, cells undergo 1-2 doublings and then cease to divide. These results can be explained by a block in cell division after the first replication cycle due either to an inability to segregate replicated chromosomes when topo IV is inhibited or to lesion accumulation during the first round of replication.
Clinical Implications. We showed that a naturally occurring E. coli mutation (E84K) in ParC makes the reconstituted topo IV 25-fold more resistant to quinolones than the wt enzyme. The E84K mutation is more likely to occur in vivo than the S80L mutation, because it requires only 1 nucleotide change instead of 2. The parCK84 and gyrAr strain was 10-fold more resistant to drugs than parC+ gyrAr and an additional 2-fold more resistant than parCL"O gyrAr. Although quinolones have been developed to inhibit DNA gyrase, it is striking that successive generations of drugs giving orders of magnitude increases in potency have increased the action on topo IV in parallel. The drug binding pockets of the two enzymes must have fundamental similarities. Topo IV has unwittingly become a clinically important drug target because of the widespread drug-resistance mutations in gyrase.
